Feed NGNE
NG

Neurogene Inc.

NGNE · NASDAQ

$32.09 -3.26% (-$1.08)
1M -19.05%
Market Cap $512.2M
P/E Ratio -
Div. Yield -
ROE 45.11%

Bulios Fair Price

$16.9

47.3% downside

Current Price

$32.09

Undervalued Fair Value Overvalued

According to Bulios Fair Price, NGNE is currently overvalued relative to its market price. How does it work?

Unlock fair price

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Piotroski F-Score Weak
1/9
Valuation
79 /100
Cheap
P/B 2.36x
P/FCF N/A
P/FFO N/A
Growth
100 /100
Growing
Book val. growth 39.00%
Rev. growth N/A
FCF growth N/A
Profitability
-
N/A
FCF margin N/A
Op. margin N/A
Gross margin N/A
Quality
0 /100
Poor
Asset turnover 0.00x
ROA 45.47%
ROIC 53.72%
Debt
69 /100
Low
Current ratio 10.64x
Int. coverage -55,554.00x
Debt/Equity 0.04x
Stability
21 /100
Unstable
EPS volatility 43.06%
Profitable years 0
Beta 1.96x

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about NGNE
Online

About the company

Neurogene Inc. is an American biopharmaceutical company focused on the development of innovative therapies for the treatment of genetic neurological disorders. The company specializes in researching and developing gene therapy-based drugs that have the potential to treat and improve the lives of patients with genetically inherited neurological disorders.

Sector

Healthcare

Industry

Biotechnology

CEO

Rachel L. McMinn

Employees

131

Headquarters

New York City

Upcoming events

12 NOV

Earnings

Upcoming earnings report

52d

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.